<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37127324</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>04</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0315-162X</ISSN><JournalIssue CitedMedium="Internet"><Volume>50</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The Journal of rheumatology</Title><ISOAbbreviation>J Rheumatol</ISOAbbreviation></Journal><ArticleTitle>Argonaute, Vault, and Ribosomal Proteins Targeted by Autoantibodies in Systemic Lupus Erythematosus.</ArticleTitle><Pagination><StartPage>1136</StartPage><EndPage>1144</EndPage><MedlinePgn>1136-1144</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3899/jrheum.2022-1327</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To expand, in an unbiased manner, our knowledge of autoantigens and autoantibodies in patients with systemic lupus erythematosus (SLE) and evaluate their associations with serological and clinical variables.</AbstractText><AbstractText Label="METHODS">Human proteome arrays (&gt; 21,000 proteins) were screened with serum from patients with SLE (n = 12) and healthy controls (n = 6) for IgG and IgA binding. Top hits were validated with 2 cohorts of patients with SLE (cohort 1, n = 49; cohort 2, n = 46) and other rheumatic diseases by ELISA. Clinical associations of the autoantibodies were tested.</AbstractText><AbstractText Label="RESULTS">Ro60 was the top hit in the screen, and the 10 following proteins included 2 additional known SLE autoantigens plus 8 novel autoantigens involved in microRNA processing (Argonaute protein 1 [AGO1], AGO2, and AGO3), ribosomes (ribosomal protein lateral stalk subunit P2 and ovarian tumor deubiquitinase 5 [OTUD5]), RNA transport by the vault (major vault protein), and the immune proteasome (proteasome activator complex subunit 3). Patient serum contained IgG reactive with these proteins and IgA against the AGO proteins. Using the 95th percentile of healthy donor reactivity, 5-43% were positive for the novel antigens, with OTUD5 and AGO1 showing the highest percentages of positivity. Autoantibodies against AGO1 proteins were more prevalent in patients with oral ulcers in a statistically significant manner. IgG autoantibodies against AGO proteins were also seen in other rheumatic diseases.</AbstractText><AbstractText Label="CONCLUSION">We discovered new autoantigens existing in cytosolic macromolecular protein assemblies containing RNA (except the proteasome) in cells. A more comprehensive list of autoantigens will allow for a better analysis of how proteins are targeted by the autoimmune response. Future research will also reveal whether specific autoantibodies have utility in the diagnosis or management of SLE.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 by the Journal of Rheumatology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moadab</LastName><ForeName>Fatemeh</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>F. Moadab, MD, X. Wang, PhD, R. Najjar, MD, C. Lood, PhD, T. Mustelin, MD, PhD, Division of Rheumatology, University of Washington, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiaoxing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>F. Moadab, MD, X. Wang, PhD, R. Najjar, MD, C. Lood, PhD, T. Mustelin, MD, PhD, Division of Rheumatology, University of Washington, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Najjar</LastName><ForeName>Rayan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>F. Moadab, MD, X. Wang, PhD, R. Najjar, MD, C. Lood, PhD, T. Mustelin, MD, PhD, Division of Rheumatology, University of Washington, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ukadike</LastName><ForeName>Kennedy C</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>K.C. Ukadike, MD, Division of Rheumatology, University of Washington, Seattle, Washington, now with Renown Rheumatology, Department of Internal Medicine, Renown Health, and University of Nevada, Reno School of Medicine, Reno, Nevada, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Shaohui</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>S. Hu, PhD, T. Hulett, PhD, CDI Laboratories, Baltimore, Maryland, USA, and Mayaguez, Puerto Rico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hulett</LastName><ForeName>Tyler</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-4128-5834</Identifier><AffiliationInfo><Affiliation>S. Hu, PhD, T. Hulett, PhD, CDI Laboratories, Baltimore, Maryland, USA, and Mayaguez, Puerto Rico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bengtsson</LastName><ForeName>Anders A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>A.A. Bengtsson, MD, PhD, Division of Rheumatology, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lood</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>F. Moadab, MD, X. Wang, PhD, R. Najjar, MD, C. Lood, PhD, T. Mustelin, MD, PhD, Division of Rheumatology, University of Washington, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mustelin</LastName><ForeName>Tomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-5912-8840</Identifier><AffiliationInfo><Affiliation>F. Moadab, MD, X. Wang, PhD, R. Najjar, MD, C. Lood, PhD, T. Mustelin, MD, PhD, Division of Rheumatology, University of Washington, Seattle, Washington, USA; tomas2@uw.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AR074939</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AR081654</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AR077266</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AR075134</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AR007108</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>J Rheumatol</MedlineTA><NlmUniqueID>7501984</NlmUniqueID><ISSNLinking>0315-162X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012269">Ribosomal Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.25.1</RegistryNumber><NameOfSubstance UI="D046988">Proteasome Endopeptidase Complex</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D060565">Argonaute Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001324">Autoantigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007070">Immunoglobulin A</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="Y">Autoantibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012269" MajorTopicYN="N">Ribosomal Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046988" MajorTopicYN="N">Proteasome Endopeptidase Complex</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060565" MajorTopicYN="N">Argonaute Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001324" MajorTopicYN="N">Autoantigens</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007070" MajorTopicYN="N">Immunoglobulin A</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">autoantibodies</Keyword><Keyword MajorTopicYN="N">proteins</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>2</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>1</Day><Hour>20</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37127324</ArticleId><ArticleId IdType="mid">NIHMS1892575</ArticleId><ArticleId IdType="pmc">PMC10524170</ArticleId><ArticleId IdType="doi">10.3899/jrheum.2022-1327</ArticleId><ArticleId IdType="pii">jrheum.2022-1327</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fava A, Petri M. Systemic lupus erythematosus: Diagnosis and clinical management. J Autoimmun 2019;96:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6310637</ArticleId><ArticleId IdType="pubmed">30448290</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Update on the diagnosis and management of systemic lupus erythematosus. Annals of the rheumatic diseases 2021;80:14&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">33051219</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsen NJ, Karp DR. Autoantibodies and SLE: the threshold for disease. Nat Rev Rheumatol 2014;10:181&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">24296678</ArticleId></ArticleIdList></Reference><Reference><Citation>Idborg H, Zandian A, Sandberg AS, et al. Two subgroups in systemic lupus erythematosus with features of antiphospholipid or Sjogren's syndrome differ in molecular signatures and treatment perspectives. Arthritis Res Ther 2019;21:62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6378708</ArticleId><ArticleId IdType="pubmed">30777133</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld Y. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum 2004;34:501&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">15505768</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter V, LaCava J, Taylor MS, et al. High Prevalence and Disease Correlation of Autoantibodies Against p40 Encoded by Long Interspersed Nuclear Elements in Systemic Lupus Erythematosus. Arthritis Rheumatol 2020;72:89&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6935427</ArticleId><ArticleId IdType="pubmed">31342656</ArticleId></ArticleIdList></Reference><Reference><Citation>Crow MK. IgG reactive with the p40 protein encoded by the LINE-1 retroelement. Arthritis Rheumatol 2019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6994324</ArticleId><ArticleId IdType="pubmed">31513361</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiochos B, Paz M, Li J, et al. Autoantibodies targeting LINE-1-encoded ORF1p are associated with systemic lupus erythematosus diagnosis but not disease activity. Clin Exp Rheumatol 2022;40:1636&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10424221</ArticleId><ArticleId IdType="pubmed">34665712</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung T, Pratt GA, Sundararaman B, et al. The Ro60 autoantigen binds endogenous retroelements and regulates inflammatory gene expression. Science 2015;350:455&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4691329</ArticleId><ArticleId IdType="pubmed">26382853</ArticleId></ArticleIdList></Reference><Reference><Citation>Markert A, Grimm M, Martinez J, et al. The La-related protein LARP7 is a component of the 7SK ribonucleoprotein and affects transcription of cellular and viral polymerase II genes. EMBO Rep 2008;9:569&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2427381</ArticleId><ArticleId IdType="pubmed">18483487</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodier JL, Zhang L, Vetter MR, Kazazian HH Jr. LINE-1 ORF1 protein localizes in stress granules with other RNA-binding proteins, including components of RNA interference RNA-induced silencing complex. Mol Cell Biol 2007;27:6469&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2099616</ArticleId><ArticleId IdType="pubmed">17562864</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodier JL, Cheung LE, Kazazian HH Jr. Mapping the LINE1 ORF1 protein interactome reveals associated inhibitors of human retrotransposition. Nucleic Acids Res 2013;41:7401&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3753637</ArticleId><ArticleId IdType="pubmed">23749060</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor MS, LaCava J, Mita P, et al. Affinity proteomics reveals human host factors implicated in discrete stages of LINE-1 retrotransposition. Cell 2013;155:1034&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3904357</ArticleId><ArticleId IdType="pubmed">24267889</ArticleId></ArticleIdList></Reference><Reference><Citation>Bengtsson AA, Sturfelt G, Truedsson L, et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000;9:664&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">11199920</ArticleId></ArticleIdList></Reference><Reference><Citation>Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003;100:2610&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC151388</ArticleId><ArticleId IdType="pubmed">12604793</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003;197:711&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2193846</ArticleId><ArticleId IdType="pubmed">12642603</ArticleId></ArticleIdList></Reference><Reference><Citation>Crow MK, Kirou KA, Wohlgemuth J. Microarray analysis of interferon-regulated genes in SLE. Autoimmunity 2003;36:481&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">14984025</ArticleId></ArticleIdList></Reference><Reference><Citation>Baechler EC, Bauer JW, Slattery CA, et al. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med 2007;13:59&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1869622</ArticleId><ArticleId IdType="pubmed">17515957</ArticleId></ArticleIdList></Reference><Reference><Citation>Bave U, Nordmark G, Lovgren T, et al. Activation of the type I interferon system in primary Sjogren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 2005;52:1185&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">15818675</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao M, Liu YJ. Regulation of TLR7/9 signaling in plasmacytoid dendritic cells. Protein Cell 2013;4:40&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3667388</ArticleId><ArticleId IdType="pubmed">23132256</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrat FJ, Meeker T, Gregorio J, et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 2005;202:1131&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2213213</ArticleId><ArticleId IdType="pubmed">16230478</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown GJ, Canete PF, Wang H, et al. TLR7 gain-of-function genetic variation causes human lupus. Nature 2022;605:349&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9095492</ArticleId><ArticleId IdType="pubmed">35477763</ArticleId></ArticleIdList></Reference><Reference><Citation>Lood C, Eriksson S, Gullstrand B, et al. Increased C1q, C4 and C3 deposition on platelets in patients with systemic lupus erythematosus--a possible link to venous thrombosis? Lupus 2012;21:1423&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">22878256</ArticleId></ArticleIdList></Reference><Reference><Citation>Lood C, Tyden H, Gullstrand B, et al. Platelet-Derived S100A8/A9 and Cardiovascular Disease in Systemic Lupus Erythematosus. Arthritis Rheumatol 2016;68:1970&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">26946461</ArticleId></ArticleIdList></Reference><Reference><Citation>Lood C, Tyden H, Gullstrand B, et al. Decreased platelet size is associated with platelet activation and anti-phospholipid syndrome in systemic lupus erythematosus. Rheumatology (Oxford) 2017;56:408&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">28031442</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu S, Xie Z, Onishi A, et al. Profiling the human protein-DNA interactome reveals ERK2 as a transcriptional repressor of interferon signaling. Cell 2009;139:610&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2774939</ArticleId><ArticleId IdType="pubmed">19879846</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong JS, Jiang L, Albino E, et al. Rapid identification of monospecific monoclonal antibodies using a human proteome microarray. Mol Cell Proteomics 2012;11:O111016253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3433917</ArticleId><ArticleId IdType="pubmed">22307071</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkataraman A, Yang K, Irizarry J, et al. A toolbox of immunoprecipitation-grade monoclonal antibodies to human transcription factors. Nat Methods 2018;15:330&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6063793</ArticleId><ArticleId IdType="pubmed">29638227</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh M, Chan JY, Ceribelli A, Vazquez del-Mercado M, Chan EK. Autoantibodies to Argonaute 2 (Su antigen). Adv Exp Med Biol 2013;768:45&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">23224964</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo H, Wang L, Bao D, et al. Novel Autoantibodies Related to Cell Death and DNA Repair Pathways in Systemic Lupus Erythematosus. Genomics Proteomics Bioinformatics 2019;17:248&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6818352</ArticleId><ArticleId IdType="pubmed">31494269</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang W, Hu C, Zeng H, et al. Novel systemic lupus erythematosus autoantigens identified by human protein microarray technology. Biochem Biophys Res Commun 2012;418:241&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">22266373</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S, Hao Q, Peng N, et al. Major vault protein: a virus-induced host factor against viral replication through the induction of type-I interferon. Hepatology 2012;56:57&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">22318991</ArticleId></ArticleIdList></Reference><Reference><Citation>Reeves WH, Pierani A, Chou CH, et al. Epitopes of the p70 and p80 (Ku) lupus autoantigens. J Immunol 1991;146:2678&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">1707916</ArticleId></ArticleIdList></Reference><Reference><Citation>Jahantigh D, Salimi S, Mousavi M, et al. Association Between Functional Polymorphisms of DNA Double-Strand Breaks in Repair Genes XRCC5, XRCC6 and XRCC7 with the Risk of Systemic Lupus Erythematosus in South East Iran. DNA Cell Biol 2015;34:360&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">25756210</ArticleId></ArticleIdList></Reference><Reference><Citation>Li F, Sun Q, Liu K, et al. The deubiquitinase OTUD5 regulates Ku80 stability and non-homologous end joining. Cell Mol Life Sci 2019;76:3861&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">30980112</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogawa-Momohara M, Muro Y, Satoh M, Akiyama M. Autoantibodies to Su/Argonaute 2 in Japanese patients with inflammatory myopathy. Clin Chim Acta 2017;471:304&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">28673815</ArticleId></ArticleIdList></Reference><Reference><Citation>Do LD, Moritz CP, Muniz-Castrillo S, et al. Argonaute Autoantibodies as Biomarkers in Autoimmune Neurologic Diseases. Neurol Neuroimmunol Neuroinflamm 2021;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8362341</ArticleId><ArticleId IdType="pubmed">34321331</ArticleId></ArticleIdList></Reference><Reference><Citation>Craft JE, Hardin JA. Linked sets of antinuclear antibodies: what do they mean? J Rheumatol Suppl 1987;14 Suppl 13:106&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">2441041</ArticleId></ArticleIdList></Reference><Reference><Citation>Mevorach D, Mascarenhas JO, Gershov D, Elkon KB. Complement-dependent clearance of apoptotic cells by human macrophages. J Exp Med 1998;188:2313&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2212421</ArticleId><ArticleId IdType="pubmed">9858517</ArticleId></ArticleIdList></Reference><Reference><Citation>Elkon KB. Review: Cell Death, Nucleic Acids, and Immunity: Inflammation Beyond the Grave. Arthritis Rheumatol 2018;70:805&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5984680</ArticleId><ArticleId IdType="pubmed">29439290</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight JS, Carmona-Rivera C, Kaplan MJ. Proteins derived from neutrophil extracellular traps may serve as self-antigens and mediate organ damage in autoimmune diseases. Front Immunol 2012;3:380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3521997</ArticleId><ArticleId IdType="pubmed">23248629</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan H, Liu F, Dong G, et al. Activation-induced necroptosis contributes to B-cell lymphopenia in active systemic lupus erythematosus. Cell Death Dis 2014;5:e1416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4225223</ArticleId><ArticleId IdType="pubmed">25210799</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P, Jiang M, Li K, et al. Glutathione peroxidase 4-regulated neutrophil ferroptosis induces systemic autoimmunity. Nat Immunol 2021;22:1107&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8609402</ArticleId><ArticleId IdType="pubmed">34385713</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>